Annual report pursuant to Section 13 and 15(d)

Strategic Alliances (Details)

v3.8.0.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended 20 Months Ended 36 Months Ended
Oct. 12, 2017
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Dec. 31, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Dec. 31, 2017
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Initial upfront payment $ 6,000,000                    
Milestone revenue recognized         $ 0            
Deferred revenue         $ 105,200,000 $ 105,200,000 $ 162,400,000   $ 105,200,000 $ 105,200,000  
Grant repayment           $ 0 0 $ 25,889,000      
Ownership percentage         4.00% 4.00%     4.00% 4.00%  
Vifor Fresenius Medical Care Pharma Ltd                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone revenue recognized                 $ 0    
Vifor Fresenius Medical Care Pharma Ltd | Development and License Agreement                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Proceeds from license fees received   $ 50,000,000       $ 50,000,000.0          
Royalty revenue, obligation period   10 years                  
Vifor Fresenius Medical Care Pharma Ltd | Exclusive Option                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum   $ 555,000,000                  
Vifor Fresenius Medical Care Pharma Ltd | Regulatory Milestones                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum   37,000,000                  
Vifor Fresenius Medical Care Pharma Ltd | Launch and Sales-based Milestones                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum   $ 195,000,000                  
TESARO                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments, maximum       $ 85,000,000.0              
Milestone payment ranges       30,000,000              
Upfront payment under license agreements       $ 6,000,000              
Maximum period to receive royalties       12 years              
TESARO | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone revenue recognized           10,000,000 $ 0 $ 15,000,000      
Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone revenue recognized                   $ 0  
Milestone payments, maximum     $ 275,000,000                
Non-refundable upfront payment     295,000,000     $ 295,000,000          
Additional milestone payment to be received     275,000,000                
Increase to revenue recognition period           1 year          
Revenue from sale of intellectual property           $ 57,800,000          
Deferred revenue         $ 101,100,000 101,100,000     101,100,000 101,100,000  
Research and development expenses related to hGH-CTP           47,700,000          
RXi Pharmaceuticals Corporation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payments                     $ 50,000,000
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue         44,900,000 44,900,000     44,900,000 44,900,000  
Other Long-term Liabilities | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue         $ 56,200,000 $ 56,200,000     $ 56,200,000 $ 56,200,000  
Minimum | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment ranges     20,000,000                
Maximum | Pfizer | Collaborative Arrangement, Product                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Milestone payment ranges     $ 90,000,000                
Pharmsynthez                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Ownership percentage         9.00% 9.00%     9.00% 9.00%  
Phase Two Initiation                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Additional milestone payments 6,000,000                    
Regulatory And Development                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Additional milestone payments 31,000,000                    
Sales Revenue                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Additional milestone payments $ 75,000,000